A group at Memorial Sloan-Kettering Cancer Center has developed T cells that express an inhibitory chimeric antigen receptor, or iCAR, in addition to a cancer-specific CAR to prevent healthy cells from activating T cell function. The team will next use the strategy to produce iCAR T cells to target cancer cells in solid tumors.